Insider Selling: Tabula Rasa HealthCare Inc (NASDAQ:TRHC) CEO Sells 8,000 Shares of Stock

Share on StockTwits

Tabula Rasa HealthCare Inc (NASDAQ:TRHC) CEO Calvin H. Knowlton sold 8,000 shares of the firm’s stock in a transaction dated Monday, August 19th. The stock was sold at an average price of $64.13, for a total value of $513,040.00. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link.

NASDAQ TRHC opened at $62.75 on Friday. The stock’s 50-day moving average price is $57.71 and its 200-day moving average price is $53.93. The company has a quick ratio of 1.90, a current ratio of 1.97 and a debt-to-equity ratio of 1.31. Tabula Rasa HealthCare Inc has a 52 week low of $40.86 and a 52 week high of $91.16. The company has a market capitalization of $1.39 billion, a P/E ratio of 184.56 and a beta of 1.63.

Tabula Rasa HealthCare (NASDAQ:TRHC) last issued its earnings results on Thursday, August 8th. The company reported $0.35 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.06 by $0.29. The company had revenue of $76.26 million for the quarter, compared to the consensus estimate of $70.40 million. Tabula Rasa HealthCare had a positive return on equity of 3.63% and a negative net margin of 7.09%. The firm’s quarterly revenue was up 56.9% on a year-over-year basis. During the same quarter last year, the company earned $0.20 EPS. Research analysts anticipate that Tabula Rasa HealthCare Inc will post -0.14 EPS for the current year.

Several research analysts have recently commented on TRHC shares. BidaskClub raised Tabula Rasa HealthCare from a “buy” rating to a “strong-buy” rating in a research note on Tuesday, August 13th. Piper Jaffray Companies raised their price objective on Tabula Rasa HealthCare from $73.00 to $78.00 and gave the stock an “overweight” rating in a research note on Thursday, May 9th. Cantor Fitzgerald reaffirmed a “buy” rating and issued a $99.00 price objective on shares of Tabula Rasa HealthCare in a research note on Monday, May 13th. TheStreet downgraded Tabula Rasa HealthCare from a “c-” rating to a “d+” rating in a research note on Tuesday, June 11th. Finally, Zacks Investment Research raised Tabula Rasa HealthCare from a “hold” rating to a “strong-buy” rating and set a $72.00 price objective on the stock in a research note on Friday, August 16th. Two investment analysts have rated the stock with a hold rating, eight have issued a buy rating and three have issued a strong buy rating to the stock. The stock currently has a consensus rating of “Buy” and a consensus target price of $83.12.

A number of institutional investors and hedge funds have recently modified their holdings of the stock. BlackRock Inc. raised its stake in Tabula Rasa HealthCare by 4.0% during the 2nd quarter. BlackRock Inc. now owns 2,752,675 shares of the company’s stock valued at $137,441,000 after purchasing an additional 105,190 shares during the period. Price T Rowe Associates Inc. MD raised its stake in Tabula Rasa HealthCare by 18.2% during the 2nd quarter. Price T Rowe Associates Inc. MD now owns 1,315,216 shares of the company’s stock valued at $65,669,000 after purchasing an additional 202,683 shares during the period. Jennison Associates LLC raised its stake in Tabula Rasa HealthCare by 3.8% during the 2nd quarter. Jennison Associates LLC now owns 918,893 shares of the company’s stock valued at $45,880,000 after purchasing an additional 33,282 shares during the period. Bank of America Corp DE raised its stake in Tabula Rasa HealthCare by 14.3% during the 2nd quarter. Bank of America Corp DE now owns 620,683 shares of the company’s stock valued at $30,991,000 after purchasing an additional 77,578 shares during the period. Finally, Artisan Partners Limited Partnership raised its stake in Tabula Rasa HealthCare by 14.2% during the 1st quarter. Artisan Partners Limited Partnership now owns 448,735 shares of the company’s stock valued at $25,318,000 after purchasing an additional 55,749 shares during the period. 95.61% of the stock is currently owned by institutional investors.

Tabula Rasa HealthCare Company Profile

Tabula Rasa HealthCare, Inc operates as a healthcare technology company in the field of medication safety in the United States. The company's proprietary Medication Risk Mitigation Matrix delivers a multi-drug review, which identifies medication-related risks. Its cloud-based software applications include EireneRx, a medication decision-support and e-prescribing platform to access patients' medication-related information; and MedWise that provides medication decision support components for clients seeking to manage their medication risk and improve medication outcomes, and patient relationships by enhancing their existing systems.

Read More: What are benefits of a growth and income fund?

Insider Buying and Selling by Quarter for Tabula Rasa HealthCare (NASDAQ:TRHC)

Receive News & Ratings for Tabula Rasa HealthCare Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Tabula Rasa HealthCare and related companies with MarketBeat.com's FREE daily email newsletter.



Latest News

EZCORP  Stock Price Down 11.5%
EZCORP Stock Price Down 11.5%
Opera  Stock Price Down 7.5%
Opera Stock Price Down 7.5%
Lexicon Pharmaceuticals  Trading Down 9.2%
Lexicon Pharmaceuticals Trading Down 9.2%
Hi-Crush  Trading Down 6.8%
Hi-Crush Trading Down 6.8%
Spi Energy  Trading Down 12.2%
Spi Energy Trading Down 12.2%
Dynagas LNG Partners  Trading Down 8.3%
Dynagas LNG Partners Trading Down 8.3%


© 2006-2019 Ticker Report